JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Home・Akciju saraksts・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Slēgts

4.61 0.66

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.47

Max

4.75

Galvenie mērījumi
By Trading Economics
Ienākumi	27M 2.5M
Pārdošana	9M 11M
Peļņas marža	23.494
Darbinieki	44
EBITDA	27M 2.6M

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	217M 857M
Iepriekšējā atvēršanas cena	3.95
Iepriekšējā slēgšanas cena	4.61

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

3.255 / 3.365 Atbalsts un pretestība

Arbutus Biopharma Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 29. okt. 23:28 UTC

Karstas akcijas

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

2025. g. 29. okt. 23:07 UTC

Peļņas

Prudential PLC 3Q New Business Profit Up 13%

2025. g. 30. okt. 00:00 UTC

Peļņas

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

2025. g. 30. okt. 00:00 UTC

Peļņas

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

2025. g. 30. okt. 00:00 UTC

Peļņas

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

2025. g. 29. okt. 23:46 UTC

Tirgus saruna

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

2025. g. 29. okt. 23:40 UTC

Peļņas

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

2025. g. 29. okt. 23:38 UTC

Tirgus saruna

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

2025. g. 29. okt. 23:25 UTC

Peļņas

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

2025. g. 29. okt. 22:51 UTC

Peļņas

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

2025. g. 29. okt. 22:45 UTC

Peļņas

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

2025. g. 29. okt. 22:41 UTC

Peļņas

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

2025. g. 29. okt. 22:41 UTC

Peļņas

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

2025. g. 29. okt. 22:09 UTC

Peļņas

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

2025. g. 29. okt. 22:08 UTC

Tirgus saruna

Peļņas

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

2025. g. 29. okt. 21:58 UTC

Peļņas

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

2025. g. 29. okt. 21:58 UTC

Peļņas

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

2025. g. 29. okt. 21:57 UTC

Peļņas

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

2025. g. 29. okt. 21:54 UTC

Peļņas

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

2025. g. 29. okt. 21:46 UTC

Peļņas

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

2025. g. 29. okt. 21:43 UTC

Peļņas

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

2025. g. 29. okt. 21:43 UTC

Peļņas

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

2025. g. 29. okt. 21:42 UTC

Peļņas

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

2025. g. 29. okt. 21:42 UTC

Peļņas

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

2025. g. 29. okt. 21:41 UTC

Peļņas

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

2025. g. 29. okt. 21:41 UTC

Peļņas

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

2025. g. 29. okt. 21:41 UTC

Peļņas

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

2025. g. 29. okt. 21:41 UTC

Peļņas

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

2025. g. 29. okt. 21:40 UTC

Peļņas

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

2025. g. 29. okt. 21:39 UTC

Peļņas

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Salīdzinājums

Cenas izmaiņa

Arbutus Biopharma Corp Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Arbutus Biopharma Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.255 / 3.365Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.